Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Drug-Receptor Interaction: Antagonist

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Drug-Receptor Interactions

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dihydroberberine regulates the ferroptosis-autophagy positive feedback loop in colorectal cancer by targeting PANX2.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026

Same author

LLM-driven human-AI collaborative decision support system for complex industrial processes: A case study in metallurgy.

Neural networks : the official journal of the International Neural Network Society·2026

Same author

HCAR1 antagonist screening based on boundary-selected negative sampling strategy and multi-level graph neural network.

Computer methods and programs in biomedicine·2026

Same author

Offline-to-online reinforcement learning with efficient unconstrained fine-tuning.

Neural networks : the official journal of the International Neural Network Society·2025

Same author

Intelligent technology leads the transformation of traditional Chinese medicine: Large models and virtual cells aid modern analysis of stroke treatment.

Pharmacological research·2025

Same author

Multi-dimensional data-driven computational drug repurposing strategy for screening novel neuroprotective agents in ischemic stroke.

Theranostics·2025

Search research articles

Related Experiment Video

Updated: May 5, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Multi-view semi-supervised adversarial attention network for drug repurposing.

Mengmeng Fan¹, Dakuo He², Qian Liu¹

¹College of Information Science and Engineering, Northeastern University, Shenyang, 110819, Liaoning, China.

Computer Methods and Programs in Biomedicine

|May 3, 2026

Summary

This summary is machine-generated.

This study introduces a new AI model, the Multi-view Semi-Supervised Adversarial Attention Network (M-SSAAN), to improve drug repositioning. M-SSAAN enhances the prediction of drug-disease associations by integrating diverse data and advanced learning techniques.

Keywords:

Attention mechanism Deep learning Drug repositioning Drug-disease associations Generative adversarial network Semi-supervised learning

Related Experiment Videos

Last Updated: May 5, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Area of Science:

Computational drug discovery
Bioinformatics
Artificial intelligence in medicine

Background:

Drug repositioning offers an efficient route to identify new therapeutic uses for existing drugs.
Current prediction methods often lack biological and chemical insights, and suffer from data sparsity and poor negative sample selection.
These limitations hinder the accuracy and reliability of drug-disease association predictions.

Purpose of the Study:

To develop an advanced computational model for predicting drug-disease associations.
To overcome the limitations of existing methods, including data sparsity and reliance on similarity data.
To enhance the robustness and accuracy of drug repositioning strategies.

Main Methods:

Proposed the Multi-view Semi-Supervised Adversarial Attention Network (M-SSAAN).
Integrated structural and similarity embeddings for multi-view representations.
Utilized attention mechanisms and semi-supervised adversarial learning to address data sparsity and improve model robustness.

Main Results:

M-SSAAN demonstrated effectiveness through comparative experiments and ablation studies.
Case studies, including ibuprofen indications and zero-shot lung cancer predictions, validated the model's predictive capabilities.
The model successfully identified reliable drug-disease associations, showcasing its practical utility.

Conclusions:

M-SSAAN shows significant potential as a robust tool for drug discovery.
The developed network effectively predicts drug-disease associations, aiding in the identification of new therapeutic applications.
This approach advances the field of computational drug repositioning.